Neuphoria Therapeutics (NEUP) Cash & Current Investments (2020 - 2026)

Neuphoria Therapeutics (NEUP) has 7 years of Cash & Current Investments data on file, last reported at $19.4 million in Q1 2026.

• Quarterly Cash & Current Investments rose 13.82% year-over-year to $19.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $19.4 million (up 13.82% YoY) and the FY2025 annual result came in at $14.3 million, up 13.33% from the prior year.
• Cash & Current Investments eased to $19.4 million in Q1 2026 per NEUP's latest filing, from $22.3 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $24.0 million in Q2 2022 and bottomed at $4.3 million in Q4 2024.
• The 5-year median for Cash & Current Investments is $12.6 million (2024), against an average of $13.4 million.
• The widest annual swing landed in 2024, when Cash & Current Investments sank 57.22%; it then soared 412.13% in 2025.
• Tracing NEUP's Cash & Current Investments over 5 years: stood at $24.0 million in 2022, then slumped by 57.76% to $10.2 million in 2023, then sank by 57.22% to $4.3 million in 2024, then soared by 412.13% to $22.3 million in 2025, then fell by 12.81% to $19.4 million in 2026.
• Per Business Quant, the three latest NEUP Cash & Current Investments figures stand at $19.4 million (Q1 2026), $22.3 million (Q4 2025), and $13.7 million (Q3 2025).

Peer Comparison